We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Case report highlights teclistamab's effectiveness in treating refractory multiple myeloma in a Jehovah's Witness, suggesting viability in similar cases.
No takes yet. Share an insight, caveat, or question.
Arepalli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: